Rosuvastatin Calcium Stabilization with Magnesium Hydroxide
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current methods for producing stable solid pharmaceutical compositions of rosuvastatin are complex and require pH adjuvants and inorganic salts of multivalent metals to prevent decomposition, while statins are sensitive to environmental conditions like light, heat, and humidity, necessitating a simpler and more stable formulation.
Innovation Solution
A pharmaceutical composition using magnesium hydroxide, calcium acetate, calcium gluconate, or aluminum hydroxide as stabilizing agents, combined with conventional excipients like lactose, microcrystalline cellulose, and magnesium stearate, which allows for dose-proportional formulation and film-coating, and a process involving sieving, blending, and compression to produce stable rosuvastatin calcium tablets.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If pH adjuvants and inorganic salts of multivalent metals are used to prevent decomposition, then stability is improved, but manufacturing complexity increases
Solution Approach 1:
The patent changes the chemical parameters of the stabilizing agent by using magnesium hydroxide, calcium acetate, calcium gluconate, or aluminum hydroxide instead of conventional inorganic salts like tribasic calcium phosphate. These alternatives provide effective stabilization while being easier to handle and formulate, thus reducing manufacturing complexity while maintaining stability.
Solution Approach 2:
The patent employs stabilizing agents that are simpler, more readily available, and easier to work with compared to complex inorganic salts. These alternatives require less stringent handling conditions and simpler formulation processes, effectively replacing complex stabilizing systems with simpler, more practical options.
2Reliability
If multiple stabilizing agents are used to prevent lactone formation and oxidation, then stability is improved, but the number of components increases
Solution Approach 1:
The patent identifies stabilizing agents like magnesium hydroxide, calcium acetate, calcium gluconate, and aluminum hydroxide that can simultaneously prevent both lactone formation and oxidation decomposition. These multi-functional agents replace the need for multiple separate stabilizing agents, reducing the total number of components while maintaining comprehensive protection against degradation pathways.
3Reliability
If conventional stabilizing agents are used, then stability is improved, but ease of formulation decreases
Solution Approach 1:
The patent employs stabilizing agents that are simpler, more readily available, and easier to work with compared to complex inorganic salts. These alternatives require less stringent handling conditions and simpler formulation processes, effectively replacing complex stabilizing systems with simpler, more practical options that improve ease of formulation.
Solution Approach 2:
The patent changes the physical and chemical parameters of the stabilizing agents to values that are more favorable for formulation. The selected agents have properties such as better solubility, lower hygroscopicity, and more compatible pH characteristics, making them easier to incorporate into dosage forms without requiring complex manufacturing procedures.
Applied Scientific Principles
This section explains which scientific principles are used to turn an abstract innovation direction into a practical engineering solution.
Function Achieved in This Case
The proposed composition demonstrates stability comparable to marketed products under stress-stability studies, with magnesium hydroxide, calcium acetate, and calcium gluconate providing effective stabilization, while aluminum hydroxide and magnesium acetate show lesser degradation, enabling the production of stable and dose-proportional rosuvastatin calcium dosage forms.
Implementation Method 1
the presence of inorganic salts of multivalent metals is also required to prevent the formation of lactone and oxidation decomposition products
Implementation Method 2
magnesium hydroxide and/or calcium acetate or calcium gluconate or calcium glycerophosphate or aluminum hydroxide as stabilizing agent
Data Source
AI summary
A pharmaceutical composition is disclosed containing amorphous rosuvastatin calcium and at least one of the following stabilizing agents: magnesium hydroxide, calcium acetate, calcium gluconate, calcium glycerophosphate, or aluminum hydroxide, together with at least one pharmaceutically acceptable excipient.